Navigation Links
Essilor : First Half 2009 Results
Date:8/26/2009

The 29.0% effective tax rate compared with a 29.4% rate for first-half 2008. The decline was mainly due to Satisloh's tax rate, which is lower than the Company average. - The share of profit from associates-VisionWeb, Sperian Protection and Transitions-which amounted to EUR10.7 million, versus EUR14.7 million in first-half 2008. Transitions' earnings were up slightly at EUR9.8 million (from EUR9.6 million in first-half 2008) while Sperian Protection's earnings were sharply lower at EUR0.9 million (compared with EUR5.1 million).

Profit attributable to equity holders of the parent was 2.1% higher, at EUR202.4 million. Earnings per share rose by 2.4% to EUR0.98.

Inventories

Inventories amounted to EUR493 million at June 30, 2009, compared with EUR475 million at year-end 2008, an increase of 3.8%. Like-for-like, the increase was 2.1%.

Investments

Capital expenditure net of divestments totaled EUR72 million or 4.3% of consolidated revenue. Financial investments net of disposals amounted to EUR60.9 million. Of this amount, acquisitions accounted for EUR36.9 million, while buybacks of shares accounted for EUR19.5 million.

    Cash Flow Statement

    EUR millions
    Net cash from operations      273  Capital expenditure net of
                                        the proceeds from asset
                                        sales                         72
    Proceeds from employee share       Change in WCR and
     issue                         16   provisions                   102
    Change in net debt             99  Dividends                     138
                                       Financial investments net
                                        of disposals                  61
                                       Effect of changes in
                                        exchange rat
'/>"/>
SOURCE Essilor
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Essilor Strengthens its Polarized Lens Distribution Network With the Acquisition of KBco
2. Essilor Acquires Prescription Laboratories in the United Kingdom and the United States
3. Essilor Enters Bulgarian Market
4. Essilor : 2007 Results
5. Essilor Strengthens its Positions in Italy - Three New Acquisitions in the United States
6. Essilors 2008 First-Quarter Report
7. Essilor Agrees to Acquire Satisloh The World Leader in Optical Manufacturing Solutions
8. Essilor - First-Half 2008 Revenue
9. Essilor Steps Up its Development in Eastern Europe
10. Essilor Agrees to Acquire Signet Armorlite
11. Essilor : 2008 Revenue

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...atory consulting firm Emergo Group recently survey...ors and industry service providers about the state...nd their outlook for 2010. , ...bal medical device regulatory consulting firm Em...nd IVD manufacturers, distributors and industry se...
(Date:11/24/2009)... be coupled with Stem Cell Therapy. , ...09 -- Entest Biomedical, Inc. (OTCBB: ENTB) anno...ufacturer of lasers regarding the development of a...Entest and used in conjunction with several stem c... These therapies are aimed at increasing efficacy ...
(Date:11/24/2009)...will be offering a free online seminar (webinar) o...d certified ophthalmologist and pioneer in LASIK s... , (Vocus) November 23, 20...nar on LASIK Vision Correction – which can b...is free to anyone attending., , ,The webinar is pr...
(Date:11/24/2009)...-USFarms,Inc.,(PinkSheets:USFM)adiversifiedsupplie...nounceithasreceivedformalcertificationapprovalbyth...M)Juiceproduct. ,, YanSkwara,CEOofUSFarms,Inc.s...edthecertificationprocesswiththeAmericanVegetarian...goaloftheAVAistoprovideawidelyrecognizedcertificat...
(Date:11/24/2009)...CountyHeathcare(LCH)isasmallhealthsystemontherugge...munities,employingmorethan1,200fullandpart-timepeo...uccessfulbackup,you,renotdoingyourjob,"saysBrooksB...hecasewithmanyhospitalsinMaine,budgetsareextremely...rotecthismissioncriticalsystems.Hedrewupaplan,went...
Breaking Medicine News(10 mins):Health News:Medical Device Industry Positive About 2010 – Survey 2Health News:Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment 2Health News:Free LASIK Surgery Webinar 2Health News:Free LASIK Surgery Webinar 3Health News:Free LASIK Surgery Webinar 4Health News:US Farms, Inc. Receives American Vegetarian Association Certification Approval for Aloe365(TM) Juice Product 2Health News:Replay 4 Customer Takes Risk, Fights for Budget to Protect Information Systems 2
... Delhi Cabinet today cleared the business model fo...ary Sciences (ILBS) being set up in the capital. /...eeting chaired by Chief Minister Sheila Dikshit wo...edical equipment would be borne by Delhi Governmen...
... Zolpidem is usually used to treat insomnia. T...ied for a period of six months by South African re...eveal that they are in a condition where keeping e... Zolpidem was given to the patients every morn...
... There appears to be a ray of hope for men, who ar...on with no remedy from available treatment measure...where the animal’s very own penile cells were used...s were introduced with a graft made from manufactu...
... Scott and Nicola Smith of Leicester parents of si...ffering from the incurable disorder Adrenoleukodys...ading to hear came true yesterday with reports ind...e nearly always male who lose sight, hearing, and ...
... The results of a new study shows that people with...to develop heart failure in middle age, the result...ome means a cluster of conditions, including obesi...disease, stroke and diabetes. A team of Swedish re...
... Researchers from the University of Florida announ...hickens with a disease that otherwise would have l...e researchers hope that the gene therapy may one d... the research, which delayed the onset of blindnes...
Other Medicine News:Health News:A Mother Passes On A Rare, Terminal Brain Disease To Her Three Children 2Health News:Gene Therapy May Help Restore Sight In Congenital blindness 2
(Date:11/24/2009)...v.24/PRNewswire/--AFOXThanksgivingDaytelevisionspe....S.remindsviewersthattheholidaysareatimetobegratef...rallthosewhofightthatbattleeachdayassurvivors,care...hehistoricreturntotheiceofcancersurvivorsScottHami...on-JohnandDavidFosterwhowillperform"HopeisAlwaysHe...
(Date:11/23/2009)...,Nov.23/PRNewswire-USNewswire/--FebeDurango-Rueda,...oparticipatinginaschemetodefraudtheExport-ImportBa...announcedAssistantAttorneyGeneraloftheCriminalDivi....GratacosoftheEx-ImBank,OfficeoftheInspectorGenera...obertsinU.S.DistrictCourtinWashingtontoaone-countc...
(Date:11/23/2009)...a.,Nov.23/PRNewswire-FirstCall/--Immucor,Inc.(Nasd...ment-reagentsystemstothebloodtransfusionindustry,t...Jaffray21stAnnualHealthCareConferenceinNewYork,NYw...TheCompany,spresentationisscheduledforTuesday,Dece...ntationwillbeavailablethroughthe"AboutUs--Investor...
Breaking Medicine Technology:FOX Thanksgiving Day Special 'Kaleidoscope' Unites Cancer Survivors on Ice and in Song to Celebrate Survivorship 2FOX Thanksgiving Day Special 'Kaleidoscope' Unites Cancer Survivors on Ice and in Song to Celebrate Survivorship 3Colombian National Pleads Guilty to Role in Defrauding the Export-Import Bank of the United States of More Than $1 Million 2Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 1Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 2Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 12813 3Video 3A New Online Film Introduces Longevinex Advantage 28TM 29 The First Resveratrol Based Dietary Supplement to Address Both Cellular and Connec 50244 1Video 3A New Online Film Introduces Longevinex Advantage 28TM 29 The First Resveratrol Based Dietary Supplement to Address Both Cellular and Connec 50244 2Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 1Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 2Vantia Therapeutics Lead Candidate VA106483 Demonstrates Positive Anti diuretic Effect in Phase IIa Trial in Nocturia 4662 3
...SAN MATEO, Calif., Oct. 3 Anthera Pharmaceuticals...developing,anti-inflammatory therapeutics for chro...y the completion of enrollment and patient dosing ...d, A-002 for stable coronary,artery disease. Data ...f,the year. "We are pleased with the rapid enroll...
...NEW YORK, Oct. 2 ImClone Systems Incorporated,(Na...SE: BMY ) today announced,that the U.S. Food and ...o,the ERBITUX(R) (Cetuximab) product labeling to i...epidermal growth factor inhibitor,(EGFR)-expressin...er,failure of both irinotecan- and oxaliplatin-bas...
Other Medicine Technology:Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 2Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 4Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 5Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 6Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 7
TPS-TL Spinal Spacer
...esorbable, osteoconductive matrix consisting of hy...ared for use in oral maxillofacial procedures as a...g Pro Osteon 200R has been FDA indicated as a bone...h bone during the healing process. Its interconnec...
O-arm Complete Multidimensional Surgical Imaging
Merlin Patient Care System
Medicine Products: